Literature DB >> 27089861

High frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilis.

E Firlag-Burkacka1, P Swiecki1, I Cielniak1, E Siwak1, J Gizinska1, E Bakowska1, J Kubicka1, P Pulik1, J Kowalski1, R Podlasin1, A Horban2.   

Abstract

BACKGROUND: Syphilis is an infection frequently seen with HIV, and European guidelines on the management of syphilis suggest that HIV-infected patients may have an increased risk of early neurological involvement, sometimes asymptomatic. Recent study shows a relationship between neurosyphilis and cerebrospinal fluid (CSF) HIV viral load (VL), which in turn may be associated with subsequent neurocognitive decline. OBJECTIVES AND METHODS: The aim of the study was estimation of the frequency of neurosyphilis among HIV-positive patients with early syphilis. The study included all patients diagnosed with early syphilis who had lumbar puncture performed in the years 2008-2012. Analysis included CSF parameters (serology, mononuclear cells, protein, glucose, chloride and lactate levels), CD4 count, serum VL and highly active antiretroviral therapy (HAART). Diagnosis of neurosyphilis was confirmed by CSF serology [positive fluorescent treponemal antibody and/or Venereal Disease Research Laboratory (VDRL) test(s)] and increased number of mononuclear cells. Statistical analysis included χ(2) tests with an accepted significance level of P < 0.05.
RESULTS: Lumbar puncture was performed in 72 patients, all men, with median age 33 (interquartile range 11) years. Neurosyphilis was confirmed in 65 (90.28%) of the patients. No statistically significant association between CSF parameters and CD4 count was found. However, statistically significant associations were found only between pleocytosis and serum VL > 1000 HIV-1 RNA copies/mL (P = 0.0451), as well as HAART treatment (P = 0.0328). The proportion of confirmed neurosyphilis cases, also in patients with low serum VDRL titres, was very high.
CONCLUSIONS: Considering the high proportion of patients who objected to having LP performed in the absence of neurological symptoms and the risk associated with this procedure, it may be preferable to use treatments with good CNS penetration in all HIV-positive patients with early syphilis.
© 2015 British HIV Association.

Entities:  

Keywords:  HIV/AIDS; neurosyphilis; syphilis

Mesh:

Substances:

Year:  2015        PMID: 27089861     DOI: 10.1111/hiv.12307

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  6 in total

1.  Lesson of the month 1: Neurosyphilis mimicking viral encephalitis and ischaemic stroke.

Authors:  Jessica Green; Nicholas Savage; Colin Jenkins; Catherine Chima-Okereke
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

2.  Management of Adult Syphilis: Key Questions to Inform the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Susan Tuddenham; Khalil G Ghanem
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 9.079

Review 3.  Human Immunodeficiency Virus in the Brain-Culprit or Facilitator?

Authors:  Luminita Ene
Journal:  Infect Dis (Auckl)       Date:  2018-02-14

4.  Lack of antiretroviral therapy is associated with higher risk of neurosyphilis among HIV-infected patients who remain serofast after therapy for early syphilis.

Authors:  Maciej Pastuszczak; Marek Sitko; Monika Bociaga-Jasik; Jakub Kucharz; Anna Wojas-Pelc
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

5.  Subacute Hypophysitis with Panhypopituitarism as First Presentation of HIV and Syphilis Coinfection.

Authors:  Rute Alves; Margarida França
Journal:  Case Rep Infect Dis       Date:  2017-04-16

6.  Consider Syphilis in Case of Lymphopenia in HIV-Infected Men Who Have Sex with Men (MSM): A Single-center, Retrospective Study.

Authors:  Georgios Sogkas; Diana Ernst; Faranaz Atschekzei; Alexandra Jablonka; Reinhold E Schmidt; Georg M N Behrens; Matthias Stoll
Journal:  Infect Dis Ther       Date:  2018-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.